Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Lifespan brain activity, β-amyloid, and Alzheimer's disease.

Jagust WJ, Mormino EC.

Trends Cogn Sci. 2011 Nov;15(11):520-6. doi: 10.1016/j.tics.2011.09.004. Epub 2011 Oct 7.

2.

Amyloid-β and cognition in aging and Alzheimer's disease: molecular and neurophysiological mechanisms.

Hampel H.

J Alzheimers Dis. 2013;33 Suppl 1:S79-86. doi: 10.3233/JAD-2012-129003. Review.

PMID:
22531423
3.

Amyloid-beta and mitochondria in aging and Alzheimer's disease: implications for synaptic damage and cognitive decline.

Reddy PH, Manczak M, Mao P, Calkins MJ, Reddy AP, Shirendeb U.

J Alzheimers Dis. 2010;20 Suppl 2:S499-512. doi: 10.3233/JAD-2010-100504. Review.

4.

Alzheimer's disease.

De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV.

Subcell Biochem. 2012;65:329-52. doi: 10.1007/978-94-007-5416-4_14. Review.

PMID:
23225010
5.

Alzheimer disease: Aβ-independent processes-rethinking preclinical AD.

Chételat G.

Nat Rev Neurol. 2013 Mar;9(3):123-4. doi: 10.1038/nrneurol.2013.21. Epub 2013 Feb 12.

6.

Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease.

Jack CR Jr, Wiste HJ, Vemuri P, Weigand SD, Senjem ML, Zeng G, Bernstein MA, Gunter JL, Pankratz VS, Aisen PS, Weiner MW, Petersen RC, Shaw LM, Trojanowski JQ, Knopman DS; Alzheimer's Disease Neuroimaging Initiative.

Brain. 2010 Nov;133(11):3336-48. doi: 10.1093/brain/awq277. Epub 2010 Oct 8.

7.

Long night's journey into the day: amyloid-β imaging in Alzheimer's disease.

Villemagne VL, Rowe CC.

J Alzheimers Dis. 2013;33 Suppl 1:S349-59. Review.

PMID:
22710919
8.

Is amyloid-β harmful to the brain? Insights from human imaging studies.

Jagust W.

Brain. 2016 Jan;139(Pt 1):23-30. doi: 10.1093/brain/awv326. Epub 2015 Nov 27. Review.

9.

Amyloid β precursor protein as a molecular target for amyloid β--induced neuronal degeneration in Alzheimer's disease.

Bignante EA, Heredia F, Morfini G, Lorenzo A.

Neurobiol Aging. 2013 Nov;34(11):2525-37. doi: 10.1016/j.neurobiolaging.2013.04.021. Epub 2013 May 25. Review.

10.

Is brain amyloid production a cause or a result of dementia of the Alzheimer's type?

Struble RG, Ala T, Patrylo PR, Brewer GJ, Yan XX.

J Alzheimers Dis. 2010;22(2):393-9. doi: 10.3233/JAD-2010-100846. Review.

11.

Mitochondrial amyloid-beta levels are associated with the extent of mitochondrial dysfunction in different brain regions and the degree of cognitive impairment in Alzheimer's transgenic mice.

Dragicevic N, Mamcarz M, Zhu Y, Buzzeo R, Tan J, Arendash GW, Bradshaw PC.

J Alzheimers Dis. 2010;20 Suppl 2:S535-50. doi: 10.3233/JAD-2010-100342.

PMID:
20463404
12.

L-3-n-butylphthalide improves cognitive impairment and reduces amyloid-beta in a transgenic model of Alzheimer's disease.

Peng Y, Sun J, Hon S, Nylander AN, Xia W, Feng Y, Wang X, Lemere CA.

J Neurosci. 2010 Jun 16;30(24):8180-9. doi: 10.1523/JNEUROSCI.0340-10.2010.

13.

Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease.

Gouras GK, Tampellini D, Takahashi RH, Capetillo-Zarate E.

Acta Neuropathol. 2010 May;119(5):523-41. doi: 10.1007/s00401-010-0679-9. Epub 2010 Mar 31. Review.

14.

Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease.

de la Monte SM.

Drugs. 2012 Jan 1;72(1):49-66. doi: 10.2165/11597760-000000000-00000. Review.

15.

Suppression of Alzheimer's disease-related phenotypes by expression of heat shock protein 70 in mice.

Hoshino T, Murao N, Namba T, Takehara M, Adachi H, Katsuno M, Sobue G, Matsushima T, Suzuki T, Mizushima T.

J Neurosci. 2011 Apr 6;31(14):5225-34. doi: 10.1523/JNEUROSCI.5478-10.2011.

16.

Beta-amyloid deposition and the aging brain.

Rodrigue KM, Kennedy KM, Park DC.

Neuropsychol Rev. 2009 Dec;19(4):436-50. doi: 10.1007/s11065-009-9118-x. Epub 2009 Nov 12. Review.

17.

Caffeine suppresses amyloid-beta levels in plasma and brain of Alzheimer's disease transgenic mice.

Cao C, Cirrito JR, Lin X, Wang L, Verges DK, Dickson A, Mamcarz M, Zhang C, Mori T, Arendash GW, Holtzman DM, Potter H.

J Alzheimers Dis. 2009;17(3):681-97. doi: 10.3233/JAD-2009-1071. Erratum in: J Alzheimers Dis. 2009 Nov;18(3):727. Wang, Lilly [corrected to Wang, Li]..

18.

Oxidatively modified proteins in Alzheimer's disease (AD), mild cognitive impairment and animal models of AD: role of Abeta in pathogenesis.

Sultana R, Perluigi M, Butterfield DA.

Acta Neuropathol. 2009 Jul;118(1):131-50. doi: 10.1007/s00401-009-0517-0. Epub 2009 Mar 14. Review.

19.

Alterations in α4β2 nicotinic receptors in cognitive decline in Alzheimer's aetiopathology.

Okada H, Ouchi Y, Ogawa M, Futatsubashi M, Saito Y, Yoshikawa E, Terada T, Oboshi Y, Tsukada H, Ueki T, Watanabe M, Yamashita T, Magata Y.

Brain. 2013 Oct;136(Pt 10):3004-17. doi: 10.1093/brain/awt195. Epub 2013 Aug 24.

PMID:
23975517
20.

Spatial patterns of brain amyloid-beta burden and atrophy rate associations in mild cognitive impairment.

Tosun D, Schuff N, Mathis CA, Jagust W, Weiner MW; Alzheimer's Disease NeuroImaging Initiative.

Brain. 2011 Apr;134(Pt 4):1077-88. doi: 10.1093/brain/awr044. Epub 2011 Mar 22.

Supplemental Content

Support Center